Leticia Manén

PhD in Chemistry and Chemical Engineering |Passionate for Medicinal Chemistry | @IQSbarcelona #SócIQS + @colemontse #Excelsior Alumni

[Leticia Manén @LManen]

Recordatorios que te hacen ver como vuela el tiempo…¿Recuerdas cuando te uniste a X? ¡Yo sí! #MiAniversarioDeX

[ESMO - Eur. Oncology @myESMO]

📣 ESMO TAT 2026 is officially LIVE!

We’re welcoming delegates in Paris as we kick off three days dedicated to early‑phase innovation and targeted anticancer therapies.
Join the #ESMOTAT26 conversation.

#ESMOMeetings

🔗 https://t.co/vGYb63OVCS

[Francisco Javier Bronchalo ن @fjbronchalo]

Carta de un cura de barrio a Silvia Abril:

Estimada Silvia:

Me llamo Francisco Javier. Soy un sacerdote del montón que vive y trabaja en un barrio obrero del sur de Madrid, en Leganés. En mi día a día no hay focos ni maquillaje; aquí la vida es muy auténtica.
👇

[jmolaizola sj @jmolaizola]

Hay heridas que no se deben cerrar en falso. Se reabren y no terminan de cicatrizar

[jmolaizola sj @jmolaizola]

Tú pon, de tu parte, lo que esté en tu mano. Y luego, acoge el resultado. Sin drama ni exceso.

[The Nobel Prize @NobelPrize]

"I think we can use AI as part of the solution if we're clever."

Today Demis Hassabis was awarded the Nobel Prize in Chemistry 2024 for developing an AI model that can predicting proteins’ complex structures. He joined us earlier this year at a Nobel Prize Dialogue event and spoke about the opportunities of AI.

Watch the full conversation: https://t.co/6u37JN33Jj

[The Nobel Prize @NobelPrize]

BREAKING NEWS
The Royal Swedish Academy of Sciences has decided to award the 2024 #NobelPrize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.”

[Albert A. Antolin (he/him) @antolin_aa]

Really proud of our review @LManen We review available data & methods for target prediction and polypharmacology & provide our expert opinion balancing the excitement around new data and AI with the remaining limitations to comprehensively predict drug selectivity! Enjoy! 👇👇👇

[Leticia Manén @LManen]

🚀𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀 𝘁𝗼 𝗦𝘁𝗮𝗿𝘁 𝘁𝗵𝗲 𝗪𝗲𝗲𝗸! Our review in Polypharmachology Prediction (w/ @antolin_aa) is now published in 𝗘𝘅𝗽𝗲𝗿𝘁 𝗢𝗽𝗶𝗻𝗶𝗼𝗻 𝗶𝗻 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆!
More things to come... stay tuned!
📖 Check it out: https://t.co/hS7BVAObll

[Leticia Manén @LManen]

So happy to share our META-PRIME project at #SLAS2024 come to 1006-A poster stand if you are interested in #repurposing , #polypharmacology , #AI in #DrugDiscovery and #cancer #research

[Leticia Manén @LManen]

3,2,1… go! Ready for #SLAS2024
Can’t wait to share the research carried out in @antolin_aa ‘s Lab from
@idibell_cat !

[Albert A. Antolin (he/him) @antolin_aa]

And @LManen was awarded 2nd best poster award for our research on repurposing drug metabolites!! Really proud! #iDR24 @REMEDi4ALL #proudPI PoC: @CellChemBiol https://t.co/sG60Tl1iU8… #DrugRepurposing

[REMEDi4ALL @REMEDi4ALL]

🌟Thanks for joining us at the #iDR24 International #DrugRepurposing Conference in Barcelona.

We look forward to our next opportunity to meet, discuss the many challenges, bust myths, share best practices & further work towards a better future for patients.

Safe journey home.

[Albert A. Antolin (he/him) @antolin_aa]

Terrific 1st day at #iDR24 conference @REMEDi4ALL if you are interested in our approach to repurpose drug metabolites come check @LManen poster summarizing our strategy and PoC on rucaparib’s metabolite just published @CellChemBiol https://t.co/uIQmt5U6Jw #DrugRepurposing.

[The Science of Parkinson's @ScienceofPD]

Interesting - @antolin_aa & colleagues explore the differential kinase selectivity of Rucaparib & its major metabolite M324; They report M324 reduced α-synuclein in dopamine neurons carrying the #Parkinsons-associated LRRK2 G2019S mutation
https://t.co/UskvQmzMxr

[Albert A. Antolin (he/him) @antolin_aa]

Thrilled to share the 1st paper from my lab @chemicalbiology https://t.co/3WF5Qae6zr Rucaparib and its major metabolite have different activity that becomes synergistic in prostate cancer lines & active in a #Parkinson model @ICR_London @ProcureICO @ICO_oncologia @idibell_cat A🧵

[Notícies en Xarxa @NoticiesEnXarxa]

💊 Un fàrmac contra el #càncer obre una nova via de tractament del #Parkinson. Ho revela un estudi d’investigadors de l’@idibell_cat, l’@ICO_oncologia i l’@IQAC_CSIC 🔊 Albert Antolín (@antolin_aa), investigador de l’@idibell_cat I l’@ICO_oncologia.

[Albert A. Antolin (he/him) @antolin_aa]

Thrilled to have contributed with @LManen to this article @STOTEN_journal lead by Demetrio Raldua @IDAEA_CSIC and with collaborators @IQSbarcelona showing that nicotine and its metabolite impair zebrafish behavior at environmental levels considered safe https://t.co/Z7DCSNA3pO

[Leticia Manén @LManen]

Last call! 😉 Any early scientist passionate for research interested in #DrugDiscovery, #CellCulture and #MachineLearning in #Cancer? Don't hesitate and join our group!🍀

[Albert A. Antolin (he/him) @antolin_aa]

We are looking for a Predoctoral Researcher in Cell Biology with an interest in Machine Learning to perform his/her PhD in our lab in Barcelona. Please share:
https://t.co/SB9Y9Gyet2
Deadline: 14th December. Interviews 18-22 December
@idibell_cat @ICO_oncologia #PhDposition

[Spanish Drug Discovery Network -SDDN @SDDNAssociation]

📆Day 2 of XV SDDN Meeting is now over. We have continued with two excellent scientific session. Likewise, great talks by exhibitors and poster award finalists. What an enjoyable event!
🛫Safe trip back home, and looking forward to meeting us again next year in Valencia.
#sddn